Emily Lukacz, MD
Urogynecology and Reconstructive Pelvic Surgery · la Jolla, CANPI 1750339446
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,892 of the $5,761 with a category attached, or 84.9%. Axonics, Inc. accounts for 93.1% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $5,392 and has fallen 98.7% since, to $69 in 2025.
Across 18 payments — averaging $320.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$5K
- C. R. Bard, Inc. & Subsidiaries$286
- Medtronic$69
- Rochester Medical Corporation$26
- AbbVie$14
Across 5 payments — averaging $1237.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$6K
What the payments were for
- Consulting fees$4,89285%
- Travel & lodging$3306%
- Food & beverage$5399%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 11 | $5,366 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $286 |
| Medtronic | 2 | $69 |
| Rochester Medical Corporation | 2 | $26 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics r-SNM System$4,988
- Bulkamid$363
How this compares
$5,761 in reported general payments places this provider in the 65th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
See all urogynecology and reconstructive pelvic surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 87 | $102,435 |
| GemtesaVibegron | 108 | $92,221 |
| Estradiol | 162 | $19,486 |
| YuvafemEstradiol | 71 | $11,639 |
| EstringEstradiol | 22 | $11,363 |
| Trospium Chloride ErTrospium Chloride | 14 | $2,695 |
| Methenamine Hippurate | 33 | $2,597 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 42 | $452 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 27 | $48 |
Paid to pharmacies, not to this prescriber.
Other urogynecology and reconstructive pelvic surgery in la Jolla
- Bruce Kahnla Jolla$79K
- Andrew BrillSan Francisco$345K
- Bilal KaakiRiverside$301K
- Savitha KrishnanMountain View$243K
- Peter CastilloLos Gatos$95K
- Jennifer GruenenfelderOrange$76K
- Traci ItoSan Francisco$68K
- Tanaz FerzandiLos Angeles$60K
- Sadikah BehbehaniCosta Mesa$53K
- Christopher TarnayLos Angeles$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.